Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
0.290
+0.040 (16.05%)
At close: Nov 20, 2024, 4:00 PM
0.268
-0.022 (-7.59%)
Pre-market: Nov 21, 2024, 8:03 AM EST
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
5.37M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPVO News
- 1 day ago - First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Accesswire
- 10 days ago - First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - Accesswire
- 14 days ago - Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - Accesswire
- 2 months ago - Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 3 months ago - Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated - Accesswire
- 3 months ago - Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update - Accesswire
- 5 months ago - Aptevo Therapeutics Announces Closing of $2.75 Million Offering - Accesswire